Our laboratory studies the genetic, epigenetic, and topological mechanisms that govern gene expression programs in normal and transformed lymphocytes. Insights from these studies will guide our strategies to create targeted epigenetic therapeutics for cancer, autoimmunity, and chronic inflammatory diseases. In addition, we are defining transcriptional regulatory switches that can be leveraged to re-engineer phenotypes of natural killer and other lymphoid cells, with the goal of enhancing their utility as adoptive cell therapeutics. Finally, our laboratory has an active research program to investigate the impact of DNA damage on chromosome conformation and chromatin-based regulation of gene expression.